Summary
Danaher Corporation announced a significant acquisition on February 25, 2019, entering into an equity and asset purchase agreement to acquire General Electric Company's Biopharma business for approximately $21.4 billion in cash. This move represents a substantial expansion for Danaher within the life sciences sector, aiming to integrate GE's Biopharma assets and operations into its existing portfolio. The transaction is subject to customary closing conditions, including antitrust approvals. This acquisition, if completed, is expected to be transformative for Danaher, bolstering its presence in a high-growth market. Investors should monitor the regulatory approval process and any further disclosures regarding integration plans and the financial impact of this large-scale transaction. The deal structure involves acquiring specific assets and assuming certain liabilities related to GE's Biopharma operations, indicating a strategic integration rather than a simple purchase of a subsidiary.
Key Highlights
- 1Danaher to acquire GE's Biopharma business for approximately $21.4 billion in cash.
- 2The acquisition is structured as an equity and asset purchase agreement with General Electric Company.
- 3The transaction is subject to customary closing conditions, including HSR Act approval and other foreign antitrust clearances.
- 4This acquisition marks a significant strategic move by Danaher into a key segment of the life sciences industry.
- 5Ancillary agreements, including intellectual property and transition services, will be entered into upon closing.
- 6A press release detailing the agreement was issued on February 25, 2019.